About EKF
EKF is a company based in Penarth (United Kingdom) founded in 1990 by Berthold Walter. EKF has raised $178.63 thousand across 2 funding rounds from investors including Renalytix Tech and Seneca Growth Capital. The company has 303 employees as of December 31, 2024. EKF has completed 6 acquisitions, including ADL Health, Advanced Diagnostic Lab and DiaSpect. EKF offers products and services including DiaSpect Tm, Biosen C-Line, Quo-Test, Lactate Scout Sport, and Beta-Hydroxybutyrate LiquiColor. EKF operates in a competitive market with competitors including LumiraDx, SpinChip, LightDeck Diagnostics, Abaxis and EDX Medical Group, among others.
- Headquarter Penarth, United Kingdom
- Employees 303 as on 31 Dec, 2024
- Founders Berthold Walter
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ekf Diagnostics Holdings Plc
-
Annual Revenue
$62.88 M (USD)-4.59as on Dec 31, 2024
-
Net Profit
$7.82 M (USD)165.39as on Dec 31, 2024
-
EBITDA
$14.01 M (USD)9.41as on Dec 31, 2024
-
Total Equity Funding
$178.63 K (USD)
in 2 rounds
-
Latest Funding Round
$28.67 M (USD), Post-IPO
Nov 01, 2018
-
Investors
Renalytix Tech
& 1 more
-
Employee Count
303
as on Dec 31, 2024
-
Investments & Acquisitions
ADL Health
& 5 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of EKF
EKF is a publicly listed company on the LSE with ticker symbol EKF in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of EKF
EKF offers a comprehensive portfolio of products and services, including DiaSpect Tm, Biosen C-Line, Quo-Test, Lactate Scout Sport, and Beta-Hydroxybutyrate LiquiColor.
Hemoglobin analyzer for diagnostics and blood donation testing.
Analyzer for glucose and HbA1C measurement in diabetes monitoring.
Rapid HbA1C tester for precise diabetes diagnostics.
Lactate and glucose device for sports performance optimization.
Reagent for detecting ketones in diabetic ketoacidosis.
People of EKF
Unlock access to complete
Funding Insights of EKF
EKF has successfully raised a total of $178.63K across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $28.67 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EKF
EKF has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Renalytix Tech and Seneca Growth Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of AI-based kidney disease diagnosis tool for healthcare professionals
|
Locked | Locked | Locked | |
|
Assets are managed for growth-oriented investments in the UK.
|
Locked | Locked | Locked |
Investor details for EKF
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EKF
EKF has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include ADL Health, Advanced Diagnostic Lab and DiaSpect.
Investment portfolio details for EKF
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
COVID-19 RT-PCR testing services are provided in San Antonio.
|
Locked | Locked | 2019 | Locked | |
|
Laboratory services including biochemistry, hematology, and microbiology are offered.
|
Locked | Locked | 2017 | Locked | |
|
Molecular diagnostics are provided for drug discovery and clinical use.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for EKF
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - EKF
Detailed financials for EKF
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ekf Comparisons
Peer comparison for EKF
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EKF
EKF operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as LumiraDx, SpinChip, LightDeck Diagnostics, Abaxis and EDX Medical Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud based diagnostics platform for point of care diagnosing
|
|
| Locked | Locked | Locked |
In-vitro diagnostic test cartridges are developed and manufactured via R&D.
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic devices for multiplex assays are developed.
|
|
| Locked | Locked | Locked |
Diagnostics company offering a comprehensive line of on-site diagnostic instruments and rapid tests
|
|
| Locked | Locked | Locked |
Medical diagnostics solutions are researched by the laboratory.
|
Detailed competitors of EKF
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ekf
Complete news archive for EKF
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EKF
EKF was founded in 1990 and raised its 1st funding round 20 years after it was founded.
EKF is headquartered in Penarth, United Kingdom. It is registered at Penarth, Wales, United Kingdom.
Julian Baines is the current CEO of EKF.
EKF is a funded company, having raised a total of $178.63K across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at EKF is 303.
Annual revenue of EKF is $62.88M as on Dec 31, 2024.
EKF Diagnostics was founded in 1990 and is headquartered in Penarth, United Kingdom. Blood analyzers for point-of-care and laboratory use are produced, with platforms focused on hematology, diabetes management, reproductive health, maternal care, and sports medicine. Laboratory equipment including centrifuges, clinical chemistry systems, immunoassays, infectious disease tests, and urine analyzers is also manufactured. Operations center on diagnostic tools for healthcare settings worldwide.
EKF offers DiaSpect Tm, Biosen C-Line, Quo-Test, Lactate Scout Sport, and Beta-Hydroxybutyrate LiquiColor.
Yes, EKF is publicly traded on LSE under the ticker symbol EKF.
EKF has made 6 acquisitions, including ADL Health, Advanced Diagnostic Lab, and DiaSpect.
EKF has 2 investors. Key investors include Renalytix Tech, and Seneca Growth Capital.
The ticker symbol of EKF is EKF on LSE.